Beranda › Kanker Paru Non-Sel Kecil › Illinois › Arlington Heights
Uji klinis Kanker Paru Non-Sel Kecil di Arlington Heights, IL
12 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Arlington Heights (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
Prospective External Control Cohort In Patients With Newly Diagnosed Advanced or Metastatic EGFR Mutant Non-Small Cell Lung Cancer
Menerima pesertaStudi observasional
- Northwest Oncology & Hematology, Elk Grove Village · 6 mi jauhnya
An External Control Arm Study in Non-Small Cell Lung Cancer
Menerima pesertaStudi observasional
- Northwest Oncology and Hematology, Rolling Meadows · 2 mi jauhnya
- Northwest Oncology and Hematology, Elk Grove · 6 mi jauhnya
- Northwest Oncology and Hematology, Hoffman Estates · 6 mi jauhnya
- dan 1 lainnya
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Menerima pesertaFase 2/3
- Local Institution - 007-883-A, Arlington Heights
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Menerima pesertaFase 3
- Illinois Cancer Specialists, Arlington Heights
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Menerima pesertaFase 3
- Northwest Oncology & Hematology, Barrington · 9 mi jauhnya
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
Menerima pesertaStudi observasional
- Advocate Good Shepherd Hospital, Barrington · 9 mi jauhnya
Uji klinis Kanker Paru Non-Sel Kecil di kota lain
- Houston, TX145 studi
- New York City, NY121 studi
- Arlington, VA104 studi
- Nashville, TN97 studi
- Boston, MA90 studi
- Los Angeles, CA87 studi
- St. Louis, MO73 studi
- Chicago, IL61 studi
- Baltimore, MD60 studi
- San Antonio, TX59 studi
- Columbus, OH57 studi
- Washington, DC55 studi
Studi lain di Arlington Heights
- Kanker Kolorektal12 studi
- Kanker Paru9 studi
- Kanker Payudara7 studi
- Gagal Jantung7 studi
- Kanker Metastatik6 studi
- Kolitis Ulseratif6 studi
- Kanker Kolon6 studi
- Kanker Ovarium5 studi
- Obesitas5 studi
- Kelebihan Berat Badan5 studi
- Kanker Prostat3 studi
- Kondisi Kulit3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.